Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2022-09-07 Regulatory Filings
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Vivo Bio Tech Limited has submitted with the exchange the copies of Newspaper Publication for Notice of 35th Annual General Meeting, Book Closure and E-Voting.
Regulatory Filings
2022-09-07 English
Vivo Bio Tech Limited has submitted with the exchange the Notice conveneing the 35th Annual General Meeting of the members of the Company
Regulatory Filings
2022-09-06 English
Vivo Bio Tech Limited has submitted with the exchange the Annual Report of the Company for the financial year 2021-2022.
Annual Report Classification · 100% confidence The document is a submission to the stock exchange (BSE Limited) dated September 6, 2022, containing the Annual Report and Notice of Annual General Meeting (AGM) for the financial year 2021-2022. The text explicitly mentions the "Annual Report for the financial year 2021-2022" and includes detailed sections typical of an annual report such as Corporate Overview, Statutory Reports, Financial Section, Board’s Report, Management Discussion and Analysis, Corporate Governance Report, and Standalone and Consolidated Financial Statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data and management commentary confirms it is the full Annual Report. Therefore, the correct classification is Annual Report (10-K).
2022-09-06 English
Vivo Bio Tech Limited has submitted with the exchange the copies of advertisement issued in newspapers, today, i.e. September 02, 2022 in 'Financial Express' in English Language and in ....
Regulatory Filings
2022-09-02 English
Vivo Bio Tech Limited has informed the exchange that the book closure for the purpose of the ensuing 35th Annual General Meeting of the Company is from Thursday, September 22, 2022 to Wednesday, ....
Regulatory Filings
2022-08-30 English
Vvo Bio Tech Limited has informed the exchange that the Board of Directors of the Company at their meeting held today, i.e. Tuesday, August 30, 2022, inter-alia, transacted and approved ....
Regulatory Filings
2022-08-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.